GreenLight Biosciences EBIT

As of the most recent data (March 2023), GRNA shows a EBIT of $-160M. That compares with $-29M in the prior-year period — down 438.2% year over year. That is below the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GRNA's EBIT is now $-160M (was $-29M) — a 438.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether GreenLight Biosciences is outperforming or lagging.

The its sector sector average EBIT is about $-63M. GreenLight Biosciences is at $-160M, which is lower that average. That is roughly 148.3% below the sector mean. Use the comparison chart on this page to see how GRNA stacks up against individual peers as well.

Tracking GRNA's ebit over time shows whether GreenLight Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-160M That compares with $-29M in the prior-year period — down 438.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has GreenLight Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-160M) with ownership activity and broader fundamentals.